Catalyst Pharmaceuticals (CPRX) Common Equity (2010 - 2026)
Catalyst Pharmaceuticals' (CPRX) quarterly Common Equity came in at $1.0 billion in Q1 2026, up 27.5% YoY from $794.3 million in Q1 2025, and up 6.12% on a QoQ basis from $954.3 million in Q4 2025.
Catalyst Pharmaceuticals (CPRX) Common Equity (2010 - 2026) Analysis & Trends
Catalyst Pharmaceuticals (CPRX) has 17 years of Common Equity data on file, last reported at $1.0 billion in Q1 2026.
- Quarterly Common Equity rose 27.5% year-over-year to $1.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 27.5% YoY) and the FY2025 annual result came in at $954.3 million, up 31.15% from the prior year.
- Common Equity improved to $1.0 billion in Q1 2026, from $954.3 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $1.0 billion in Q1 2026 to a low of $220.2 million in Q1 2022.
- A 5-year average of $563.1 million and a median of $561.4 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity grew 23.27% — and 2024, when it surged 89.63%.
- Tracing CPRX's Common Equity over 5 years: stood at $300.4 million in 2022, then increased by 29.11% to $387.9 million in 2023, then jumped by 87.59% to $727.6 million in 2024, then soared by 31.15% to $954.3 million in 2025, then advanced by 6.12% to $1.0 billion in 2026.
- The last three Common Equity figures came in at $1.0 billion (Q1 2026), $954.3 million (Q4 2025), and $920.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn | 1.01 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.01 Bn |
| Dec 31, 2025 | 954.27 Mn |
| Sep 30, 2025 | 920.25 Mn |
| Jun 30, 2025 | 856.03 Mn |
| Mar 31, 2025 | 794.28 Mn |
| Dec 31, 2024 | 727.63 Mn |
| Sep 30, 2024 | 660.94 Mn |
| Jun 30, 2024 | 608.66 Mn |
| Mar 31, 2024 | 561.41 Mn |
| Dec 31, 2023 | 387.88 Mn |
| Sep 30, 2023 | 348.55 Mn |
| Jun 30, 2023 | 375.29 Mn |
| Mar 31, 2023 | 333.66 Mn |
| Dec 31, 2022 | 300.42 Mn |
| Sep 30, 2022 | 270.04 Mn |
| Jun 30, 2022 | 241.09 Mn |
| Mar 31, 2022 | 220.22 Mn |
| Dec 31, 2021 | 206.83 Mn |
| Sep 30, 2021 | 198.66 Mn |
| Jun 30, 2021 | 188.94 Mn |